Our Board of Directors

Our 20-strong team boasts deep experience in RNA biology, bioinformatics analytics, neuro-translation and development.

Meenu Chhabra Karson

Chair, Independent Director

  • Samsara Therapeutics: Executive Chair (current)
  • Macrogeneics: Director (current)
  • Apexigen: Chair
  • Proteostasis, Allozyne: President, CE
  • Novartis: VP, Business Development

Christian Jung

Investor Director, Dementia Discover Fund

  • Dementia Discovery Fund: Partner
  • Wellington: Principal
  • Gründerfonds: Senior Investment manager
  • MSc degree in Molecular Biotechnology
  • PhD with distinction in Medical Science and Technology

Mary Canning

Observer, Expidarex Capital

  • Partner: Epidarex Capital
  • Director: Caldan Therapeutics, LUNAC Therapeutics and Glasgow University Holdings Ltd
  • Commercialised academic research with MRC Technology
  • PhD and postdoctoral research in molecular biology

Dirk Landgraf

Observer, Dementia Discovery Fund

  • SV Health Investors: Principal and Dementia Discovery Fund
  • Biogen: External Innovation and Business Development
  • Whitehead/MIT: Postdoctoral research on protein misfolding toxicities
  • PhD Systems Biology, Harvard Medical School

Miles Gerson

Investor Director, Takeda Ventures

  • Takeda Ventures – Global Head & President of Takeda’s strategic investment fund
  • 15+ years of experience in life science venture investing, business development, licensing, and technology transfer, internationally
  • JD/MBA in Strategic Management in Life & Engineering Sciences from the University of Wisconsin, Madison
  • BA/MA in Neuroscience from Wesleyan University, CT

Alan Boyd

Independent Director

  • Boyd Consultants – Founder & CEO
  • Ark Therapeutics Ltd – R&D Director
  • Zeneca Pharmaceuticals – Global Head Medical Research
  • MB ChB, FRCP, FFPM, FMedSci

Michael Jones

Independent Director

  • Co-founder Harness Therapeutics
  • Chugai Pharmaceuticals – Senior Research Scientist
  • ReproCELL - COO
  • Cell Guidance Systems – CEO
  • PhD University of Newcastle

Jan Thirkettle

CEO Director

  • Freeline Therapeutics – CEO and CDO
  • GSK – Discovery to Manufacturing
  • Strimvelis – the first ex vivo gene therapy approved by EMA
  • MA in Chemistry and a DPhil in Biological Chemistry, University of Oxford

Our vision

Building the leading platform for physiological upregulation of neurodegenerative disease targets to enable truly disease-modifying therapies.

Our approach

Deep expertise & unique capabilities in RNA biology & neurodegeneration

High value targets

Ready to scale

Learn more

Our programmes

Preventing the progression of Huntington’s Disease

Discover more

Our news

View all